Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis Study Supports Chemopreventive Effect of Statins on Liver Cancer in NASH Cirrhosis
New research provides supporting evidence for chemopreventive effects of statins on hepatocellular carcinoma in patients with nonalcoholic steatohepatitis cirrhosis.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 20, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Hepatocellular Carcinoma, Novel Therapies on the Horizon Hepatocellular Carcinoma, Novel Therapies on the Horizon
Recent advancements have led to the identification and development of potential new treatment options for hepatocellular carcinoma.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - July 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Study sheds light on precise personalized hepatocellular carcinoma medicine
(Dalian Institute of Chemical Physics, Chinese Academy Sciences) Scientists identified hepatocellular carcinoma (HCC) subtypes with distinctive metabolic phenotypes through bioinformatics and machine learning methods, and elucidated the potential mechanisms based on a metabolite-protein interaction network and multi-omics data. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - July 12, 2021 Category: Cancer & Oncology Source Type: news

Tislelizumab Benefit in HCC Undimmed by Prior Therapies Tislelizumab Benefit in HCC Undimmed by Prior Therapies
Patients with advanced hepatocellular carcinoma (HCC) can achieve durable responses, and overall survival is"encouraging" with the novel immunotherapy, even after multiple prior therapies.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 6, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

More Frequent Ultrasound Screening for People at High Risk for Liver Cancer May Be Worth It More Frequent Ultrasound Screening for People at High Risk for Liver Cancer May Be Worth It
Regular ultrasound screening with an interval between six and 12 months or less may lead to earlier detection of hepatocellular carcinoma in high-risk patients, according to a study from Taiwan.Reuters Health Information (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - July 2, 2021 Category: Gastroenterology Tags: Hematology-Oncology News Source Type: news

Oncotarget: Treatment outcomes in patients with advanced hepatocellular carcinoma
(Impact Journals LLC) In CTP class A patients, IGF/CTP score B was associated with shorter PFS and OS (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 28, 2021 Category: Cancer & Oncology Source Type: news

Genetic study of liver cancer reveals new drug target
(PLOS) Drugs targeting the gene MAGEA3 may help block the growth of hepatocellular carcinoma (HCC), the most common type of primary liver cancer and one of the leading causes of cancer deaths in the country. That's one conclusion of a new study analyzing the genetics of HCC tumors published June 24th in the journal PLOS Genetics by Augusto Villanueva of the Icahn School of Medicine at Mount Sinai and colleagues. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 24, 2021 Category: Cancer & Oncology Source Type: news

MD Anderson research highlights for June 16, 2021
(University of Texas M. D. Anderson Cancer Center) The University of Texas MD Anderson Cancer Center's Research Highlights provides a glimpse into recently published studies in basic, translational and clinical cancer research from MD Anderson experts. Current advances include a new combination therapy for acute myeloid leukemia (AML), a greater understanding of persistent conditions after AML remission, the discovery of a universal biomarker for exosomes, the identification of a tumor suppressor gene in hepatocellular carcinoma (HCC) and characterization of a new target to treat Clostridioides difficile (C. difficile) inf...
Source: EurekAlert! - Cancer - June 16, 2021 Category: Cancer & Oncology Source Type: news

Neoadjuvant and Adjuvant Treatment Approaches for HCC Neoadjuvant and Adjuvant Treatment Approaches for HCC
Learn more about the current neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma and the promising new options on the horizon.Chinese Clinical Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

Toward the first drug to treat a rare, lethal liver cancer
(Rockefeller University) After scouring more than 5,000 compounds, scientists have identified several new classes of therapeutics that may help treat fibrolamellar carcinoma. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: The drug sensitivity of hepatocellular cancer cells
(Impact Journals LLC) 'Hepatocellular carcinoma (HCC) is the third leading cause of cancer related death worldwide, with a poor median survival time after diagnosis of six months.' (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 7, 2021 Category: Cancer & Oncology Source Type: news

Oncotarget: Inflammatory microenvironment & hepatic macrophage in hepatocellular carcinoma
(Impact Journals LLC) " The incidence of hepatocellular carcinoma (HCC) is increasing worldwide, and HCC is amongst the leading causes of cancer death globally. " (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 4, 2021 Category: International Medicine & Public Health Source Type: news

Transarterial embolisation not cost effective vs sorafenib for hepatocellular carcinoma
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2021 Category: Drugs & Pharmacology Source Type: news

Indigenous Americans: Global DNA pattern and gene expression signature in liver cancer
(Impact Journals LLC) Hepatocellular carcinoma (HCC), the main form of primary liver cancer, is one of the leading causes of tumor-related death worldwide. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 31, 2021 Category: Cancer & Oncology Source Type: news

HCV Cure Before HCC Diagnosis Associated With Improved Survival HCV Cure Before HCC Diagnosis Associated With Improved Survival
Do patients with HCV-related hepatocellular carcinoma who have achieved HCV cure before HCC diagnosis have improved survival compared with patients who are viraemic at HCC diagnosis?Journal of Viral Hepatitis (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - May 25, 2021 Category: Transplant Surgery Tags: Gastroenterology Journal Article Source Type: news

Bariatric Surgery Reduces the Incidence of HCC Bariatric Surgery Reduces the Incidence of HCC
This study assessed the impact of bariatric surgery on the incidence of hepatocellular carcinoma in obese patients.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - May 17, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Landmark study launched to detect liver cancer early in Singapore
(SingHealth) Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.The study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.The study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2021 Category: Cancer & Oncology Source Type: news

Landscape study launched to detect liver cancer early in Singapore
(Duke-NUS Medical School) - Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 3, 2021 Category: International Medicine & Public Health Source Type: news

Landmark study launched to detect liver cancer early in Singapore
(Duke-NUS Medical School) - Only 20% of primary liver cancer or hepatocellular carcinoma (HCC) are diagnosed at an early stage, which makes early detection an urgent, unmet healthcare need.- Study aims to develop more accurate diagnostics for early HCC, an AI algorithm to predict an individual's risk of developing HCC, and discover novel molecular targets to prevent the development of HCC.- Study aims to recruit 2,000 participants at high risk of developing HCC from six healthcare institutions and eight polyclinics across Singapore. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - May 3, 2021 Category: Cancer & Oncology Source Type: news

Cost-effectiveness evidence of hepatocellular carcinoma screening reviewed
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - May 1, 2021 Category: Drugs & Pharmacology Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Media News - April 27, 2021 Category: Pharmaceuticals Source Type: news

US FDA Advisory Committee votes in favour of maintaining accelerated approval of Roche ’s Tecentriq for PD-L1-positive, metastatic triple-negative breast cancer
This study did not meet its primary endpoint of PFS for the initial (first-line) treatment of people with mTNBC in the PD-L1-positive population. As the clinically meaningful benefit demonstrated in the IMpassion130 study remains, Roche looks forward to continuing to work with the FDA to determine next steps with regard to Tecentriq in this indication.Roche remains committed to following the science to better understand cancer, including which patients may benefit most from immunotherapy treatment. Tecentriq has already demonstrated its transformational role in areas of high medical need and is a first in class medicine ap...
Source: Roche Investor Update - April 27, 2021 Category: Pharmaceuticals Source Type: news

Antibiotics May Prolong PFS in HCC Patients on Immunotherapy Antibiotics May Prolong PFS in HCC Patients on Immunotherapy
Taking antibiotics 30 days before or after starting an immune checkpoint inhibitor was associated with a benefit in progression-free survival (PFS) for patients with hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 21, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Detecting Antibodies to p16 Protein-Derived Peptides in HCC Detecting Antibodies to p16 Protein-Derived Peptides in HCC
This study suggests that circulating IgG antibodies to p16 protein might be a useful biomarker for hepatocellular carcinoma prognosis assessment as well as early HCC diagnosis.Laboratory Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 21, 2021 Category: Consumer Health News Tags: Pathology & Lab Medicine Journal Article Source Type: news

New Combo Shows Benefit Even in Patients With High-Risk HCC New Combo Shows Benefit Even in Patients With High-Risk HCC
Updated data from the IMBRave150 trial show benefit for the combination of atezolizumab with bevacizumab even in patients with high-risk hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 14, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Monofocal Hepatocellular Carcinoma: How Much Does Size Matter? Monofocal Hepatocellular Carcinoma: How Much Does Size Matter?
This study evaluated the appropriate staging of large monofocal hepatocellular carcinomas. How should tumor size impact treatment?Liver International (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 25, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Sirtex Medical announces new SIR-Spheres(R) DOORwaY-90 Study: The first prospective multicenter U.S.-based trial for registration as first-line treatment for hepatocellular carcinoma
WOBURN, Mass., March 22, 2021 -- (Healthcare Sales & Marketing Network) -- Sirtex Medical ("Sirtex"), a leading manufacturer of targeted liver cancer therapies, announced full FDA approval of the DOORwaY90 Study, a trial evaluating the safety an... Devices, Oncology Sirtex Medical, SIR-Spheres, Y-90 resin microspheres, hepatocellular carcinoma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Investor Update - March 22, 2021 Category: Pharmaceuticals Source Type: news

Pivotal Phase III study shows Roche ’s Tecentriq helped people with early lung cancer live longer without their disease returning
Basel, 22 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Phase III IMpower010 study evaluating Tecentriq® (atezolizumab), compared with best supportive care (BSC), met its primary endpoint of disease-free survival (DFS) at the interim analysis. Tecentriq showed a statistically significant im provement in DFS as adjuvant therapy following surgery and chemotherapy in all randomised Stage II-IIIA populations with non-small cell lung cancer (NSCLC). The magnitude of DFS benefit was particularly pronounced in the PD-L1-positive population. Follow-up will continue with planned analyses of DFS ...
Source: Roche Media News - March 22, 2021 Category: Pharmaceuticals Source Type: news

Janssen Announces U.S. FDA Approval of PONVORY ™ (ponesimod), an Oral Treatment for Adults with Relapsing Multiple Sclerosis Proven Superior to Aubagio® (teriflunomide) in Reducing Annual Relapses and Brain Lesions
TITUSVILLE, N.J. – (March 19, 2021) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) approved PONVORY™ (ponesimod), a once-daily oral selective sphingosine-1-phosphate receptor 1 (S1P1) modulator, to treat adults with relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease.1,2,3 PONVORY™ offers MS patients superior efficacy in reducing annualized relapse rates compared to an established oral therapy and a proven safety profi...
Source: Johnson and Johnson - March 19, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Treatment is the only radioembolization treatment approved for U.S. patients with hepatocellular carcinoma MARLBOROUGH, Mass., March 18, 2021 -- (Healthcare Sales & Marketing Network) -- Boston Scientific Corporation (NYSE: BSX) announced it has receiv... Devices, Oncology, FDA Boston Scientific, TheraSphere, Y-90, Glass Microspheres, radioembolization (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - March 18, 2021 Category: Pharmaceuticals Source Type: news

Integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma
(Compuscript Ltd) Announcing a new article publication forBIO Integration journal. In this article the authors Jingdun Xie, Zhenhua Qi, Xiaolin Luo, Fang Yan, Wei Xing, Weian Zeng, Dongtai Chen and Qiang Li; from Sun Yat-sen University, Guangzhou, Guangdong, China discuss integration analysis of m6A regulators and m6A-related genes in hepatocellular carcinoma (HCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 9, 2021 Category: International Medicine & Public Health Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Media News - March 8, 2021 Category: Pharmaceuticals Source Type: news

Roche provides update on Tecentriq US indication in prior-platinum treated metastatic bladder cancer
This study did not meet its primary endpoint of overall survival in the PD-L1 high patient population. Subsequently, the FDA designated the IMvigor130 study as the PMR which will still continue until the final analysis. However, as the treatment landscape in prior-platinum (second-line) mUC has rapidly evolved with the emergence of new treatment options, Roche is voluntarily withdrawing this indication in recognition of the principles of the Accelerated Approval Program.About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called Programmed Death Ligand-1 (PD-L1), which is expressed on tumour c...
Source: Roche Investor Update - March 8, 2021 Category: Pharmaceuticals Source Type: news

Inovio spinout Geneos closes $12M financing round to advance personalized cancer therapy
The Montgomery County biopharmaceutical company's initial target is a type of liver cancer known as advanced hepatocellular carcinoma. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 4, 2021 Category: Biotechnology Authors: John George Source Type: news

Risk Factors for Development of HCC in Chronic HBV Infection Risk Factors for Development of HCC in Chronic HBV Infection
How do various metabolic factors and comorbidities influence hepatocellular carcinoma risk in patients with chronic hepatitis B infection?Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2021 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Liver Cancer Profile Differs in Black Patients With Hep C
THURSDAY, Feb. 25, 2021 -- Black patients with hepatitis C virus (HCV) infection develop hepatocellular carcinoma (HCC) at an earlier disease stage and have better liver function at the time of diagnosis, according to a study published online Feb.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 25, 2021 Category: Pharmaceuticals Source Type: news

ASCO Announces New Advanced Liver Cancer Guidelines ASCO Announces New Advanced Liver Cancer Guidelines
New guidelines from the American Society of Clinical Oncology were released to address the treatment of advanced hepatocellular carcinoma.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 24, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Cancer control: Non-DNA changes induce metabolism variations in hepatocellular carcinomas
(Cactus Communications) Mechanisms underlying metabolic variations in hepatocellular carcinoma (HCC), a fast growing and invasive cancer, remain unclear. Now, researchers from Fudan University, China identified signatures of " m6A, " the most abundant " post-transcriptional RNA modification, " that segregate HCC into sub-types with distinct metabolic characteristics. They have also developed a novel m6A score that can quantify such modifications and aid risk assessment, prediction of prognosis, and response to treatment in patients with HCC. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 22, 2021 Category: Cancer & Oncology Source Type: news

Drug 'breakthrough' gives longest-ever survival in nonresectable liver cancer patients
(Spink Health) New follow-up data from a landmark study of liver cancer patients treated with a combination of an immunotherapy drug (atezolizumab) and a monoclonal antibody (bevacizumab) has shown the longest-ever survival time in a frontline phase 3 trial of systemic therapy in advanced hepatocellular carcinoma (HCC), demonstrating a 'major breakthrough' in the field. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - February 5, 2021 Category: Cancer & Oncology Source Type: news

Janssen to Highlight Robust Solid Tumor Portfolio and Pipeline at 2021 ASCO GU
February 2, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it will highlight the depth of its solid tumor portfolio at the American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium with 12 data presentations, including three company-sponsored oral presentations from the ERLEADA® (apalutamide) clinical development program. The virtual meeting will take place February 11-13, 2021. “We are committed to the development of innovative therapies for patients with genitourinary cancers for whom there remains a high unmet need,” said C...
Source: Johnson and Johnson - February 2, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer Lasting Benefit With Nivo Plus Ipi in Advanced Liver Cancer
Long-term follow-up data show a continued benefit in advanced hepatocellular carcinoma (HCC) with nivolumab and ipilimumab after disease progression on sorafenib in the Checkmate 040 trial.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 1, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Oncotarget: Prognostic biomarker for patients with hepatocellular carcinoma
(Impact Journals LLC) Reduced expression of TBX15 in tumor tissue represents a potential biomarker for predicting poor survival of patients with HCC (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 25, 2021 Category: Cancer & Oncology Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Media News)
Source: Roche Media News - January 12, 2021 Category: Pharmaceuticals Source Type: news

Roche to present updated data confirming Tecentriq in combination with Avastin substantially improves overall survival in people with the most common form of liver cancer
Basel, 12 January 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) will present updated overall survival (OS) data from the Phase III IMbrave150 study evaluating Tecentriq ® (atezolizumab) in combination with Avastin® (bevacizumab), compared with sorafenib, in people with unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy. (Source: Roche Investor Update)
Source: Roche Investor Update - January 12, 2021 Category: Pharmaceuticals Source Type: news

Leaps-Bayer-leads-USD-million-Series-B-financing-Senti-Bio-develop-next-generation-therapies-using
Senti Bio’s gene circuit technology platform has the potential to optimize cell and gene therapies across delivery modalities and therapeutic areas / Proceeds to support platform expansion and advance multiple allogeneic CAR-NK cell therapy pipeline candidates for difficult-to-treat cancers, including acute myeloid leukemia and hepatocellular carcinoma (Source: Bayer Company News)
Source: Bayer Company News - January 6, 2021 Category: Pharmaceuticals Source Type: news

Liver cancer cells manipulate stromal cells involved in fibrosis to promote tumor growth
(Osaka University) Researchers led by Osaka University have found that liver cancer cells induce autophagy in hepatic stellate cells, causing them to produce a growth factor called GDF15 that promotes tumor growth. GDF15 was more highly expressed in tumor tissue than normal liver tissue, and patients with higher levels of GDF15 had a poorer prognosis. New therapies targeting GDF15 may help prevent the development and proliferation of hepatocellular carcinoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 6, 2021 Category: International Medicine & Public Health Source Type: news

Survival Rate for Hepatocellular Carcinoma
What Is the Survival Rate for Hepatocellular Carcinoma? (Source: eMedicineHealth.com)
Source: eMedicineHealth.com - January 5, 2021 Category: General Medicine Source Type: news

Fibroscan Liver Stiffness After Anti-viral Treatment for HCV Fibroscan Liver Stiffness After Anti-viral Treatment for HCV
This study investigated whether liver stiffness pre- or post-anti-viral therapy is associated with the development of decompensated cirrhosis, hepatocellular carcinoma, or death.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 16, 2020 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

New treatment options for those with liver cancer
Sharon Silverman loves to travel. But after doctors in her hometown of Pensacola, Florida, diagnosed her with hepatocellular carcinoma and told her there were no treatment options, Sharon knew she had to take one more trip. Her destination: Mayo Clinic -- where a unique radiation procedure opened the door to future adventures. Reporter DeeDee Stiepan [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 2, 2020 Category: Databases & Libraries Source Type: news